Lomeli, B. K., Galbraith, H., Schettler, J., Saviolakis, G. A., El-Amin, W., Osborn, B., . . . Janjic, N. (2019). Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent with Minimal Disruption of Normal Gut Microbiota. Antimicrob Agents Chemother.
Chicago Style CitationLomeli, Barbara K., et al. "Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent With Minimal Disruption of Normal Gut Microbiota." Antimicrob Agents Chemother 2019.
Cita MLALomeli, Barbara K., et al. "Multiple-Ascending-Dose Phase 1 Clinical Study of the Safety, Tolerability, and Pharmacokinetics of CRS3123, a Narrow-Spectrum Agent With Minimal Disruption of Normal Gut Microbiota." Antimicrob Agents Chemother 2019.